GLP-1 Drugs and Breast Cancer: Science, Safety, and Solutions
Thu, Feb 13
|Webinar
Join Drs. Ruth Oratz, Medical Oncologist, and Barrie Weinstein, Endocrinologist, on Thursday, February 13th as Sharsheret hosts a timely and important conversation on breast cancer and GLP-1 drugs.
Time & Location
Feb 13, 2025, 8:00 PM – 9:00 PM EST
Webinar
About the event
Featured Speakers
Dr. Ruth Oratz, Medical OncologistDr. Oratz is a highly respected oncologist with extensive experience in breast cancer research, patient care, and survivorship. She is known for her compassionate approach and her commitment to advancing cutting-edge treatments that improve both patient outcomes and quality of life.
Dr. Barrie Weinstein, EndocrinologistDr. Weinstein is a board-certified endocrinologist specializing in hormonal and metabolic disorders. She brings a comprehensive understanding of how GLP-1 drugs function beyond weight management and how they may benefit—or require caution—in patients with breast cancer.
Event Details
Topic: GLP-1 Drugs and Breast Cancer: Science, Safety, and Solutions
Date & Time: Thursday, February 13th, 8:00 pm EST
Registration Link: Click here to register
Why Attend?
Latest Research: Learn about cutting-edge findings on GLP-1 drugs—commonly used for weight loss—but also offering potential benefits and considerations for those with breast cancer.
Expert Insights: Drs. Oratz and Weinstein will discuss current scientific evidence and practical implications for patient care, referencing notable sources like Oprah.com and Newsweek.
Clinical Applications: From hormonal interactions to cancer-specific guidelines, gain firsthand knowledge to inform discussions with colleagues, patients, and caregivers.
Questions?
If you have any inquiries or would like more information, please contact Melissa Rosen at Sharsheret.
We encourage you to attend this insightful session to stay at the forefront of current breast cancer treatment options and the evolving role of GLP-1 drugs. Feel free to share this invitation with colleagues or community members who may also benefit.
Thank you for your steadfast commitment to the health and well-being of our community.
Program Sponsors
and the Cooperative Agreement 24-0061 of the Centers for Disease Control and Prevention.
Program Partners
